SpeeDx Receives TGA Approval for PlexPCR™ HSV-1&2, VZV
SpeeDx Pty. Ltd. has received TGA approval for its PlexPCR® HSV-1&2, VZV multiplex qPCR kit. The test offers a single-well solution to cover the detection and differentiation of three herpes...
SpeeDx Pty. Ltd. has received TGA approval for its PlexPCR® HSV-1&2, VZV multiplex qPCR kit. The test offers a single-well solution to cover the detection and differentiation of three herpes...
A recent article posted in Clinical Lab Products (CLP) by Professor Sepehr Tabrizi, Royal Women’s Hospital, Melbourne, describes our current understanding of Mycoplasma genitalium, the rise of treatment failure due...
SpeeDx has received CE-IVD marking for its PlexPCR® HSV-1&2, VZV multiplex qPCR kit. The new multiplex molecular diagnostic test offers a single-well solution to cover the detection and differentiation of three...
Announcing the first publication for our ResistancePlus® MG assay, published in PLOS ONE in collaboration with Sepehr Tabrizi, PhD at the Royal Women’s Hospital in Melbourne, Australia. “The SpeeDx assay provides...
SpeeDx are featured in a great article in GenomeWeb discussing Mycoplasma genitalium, and the antibiotic resistance status of this significant sexually transmitted disease. Read all about our ResistancePlus® MG test and our...
The establishment of a European subsidiary company, SpeeDx Limited, headquartered in the London Bioscience Innovation Centre, will support the future launch of SpeeDx PlexPCR® multiplex qPCR assays in the region. “We...
Dr. Elisa Mokany, SpeeDx’ co-founder and VP of R&D, is featured in an editorial article on Mycoplasma genitalium. The article summarises the need for molecular testing not only to identify...
Sydney, Australia (April 8, 2016) – SpeeDx Pty, Ltd. today announced that it will feature its PlexPCR® for detection of infectious disease pathogens and the unique ResistancePlus® multiplex qPCR test for...
– Goffin’s distribution channels will allow broader availability and accessibility of SpeeDx diagnostics in the Benelux market – SYDNEY, AUSTRALIA–(March 21, 2016). SpeeDx Pty, Ltd. today announced a distribution agreement with...
Austrade’s Success Stories article highlights our focus in tackling the growing threat of antimicrobial resistance using precision medicine. SpeeDx develops clinical diagnostic tests which are faster and more accurate in...
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |